Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

China Medical Acquires HPV Diagnostic Test for $345 Million

publication date: Oct 7, 2008

China Medical Technologies, which produces in-vitro diagnostic products, will pay $345 million to purchase the rights for a human papillomavirus (HPV) test from Molecular Diagnostics Technologies Limited. China Medical will buy the HPV-DNA Biosensor Chip and Surface Plasmon Resonance-based Analysis System (the SPR System), which can detect the virus that causes cervical cancer and sexually transmitted disorders. China Medical has profited by acquiring other in vitro technologies, most recently the FISH (Fluorescent in situ Hybridization) system. The SPR System will become part of the company’s FISH offerings. More details...

Stock Symbol: (NSDQ: CMED)



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital